ライフサイエンスコーパス: breast cancer case

1 median follow-up, 8.9 years; 1,905 invasive breast cancer cases).

2 at MR imaging--was similarly matched to each breast cancer case.

3 ded 301 premenopausal and 399 postmenopausal breast cancer cases.

4 clin D1 is overexpressed in about 35% of all breast cancer cases.

5 f BRCA2 account for about 10-30% of familial breast cancer cases.

6 ignificantly with Drg-1 in both prostate and breast cancer cases.

7 xifene for 4 years would have avoided 47% of breast cancer cases.

8 d 41 randomly selected, age-matched sporadic breast cancer cases.

9 and BRCA1 are responsible for most familial breast cancer cases.

10 may be associated with a large proportion of breast cancer cases.

11 aplasia and cancer was studied in a panel of breast cancer cases.

12 rm-line RAD52 alleles from 5% of early-onset breast cancer cases.

13 onic polyps, no examples were found in these breast cancer cases.

14 ions may account for approximately 5% of all breast cancer cases.

15 unt for a comparable percentage of inherited breast cancer cases.

16 umors account for up to approximately 50% of breast cancer cases.

17 nding domain of the FOXN3 gene in the Indian breast cancer cases.

18 the prestudy-enrollment data including 5,487 breast cancer cases.

19 t strategies to prevent cancer metastasis in breast cancer cases.

20 gene is mutated in approximately 30% of all breast cancer cases.

21 sting to an increasingly unselected group of breast cancer cases.

22 gistry-based cohort included 60,773 invasive breast cancer cases.

23 those women who were cancer-free, and among breast cancer cases.

24 sterone receptor status among postmenopausal breast cancer cases.

25 ne-a gene prominently responsible for 70% of breast cancer cases.

26 ss that causes TP53 mutations in a subset of breast cancer cases.

27 5 person-years, we identified 3,549 incident breast cancer cases.

28 er-volume surgeons with a high percentage of breast cancer cases.

29 e, facility type and location, and volume of breast cancer cases.

30 r carcinoma (ILC) accounts for 8%-14% of all breast cancer cases.

31 ulation structure and evolution in two human breast cancer cases.

32 of them accounting for roughly one third of breast cancer cases.

33 Of the 288 breast cancer cases, 19 (6.6%) inherited disease-predisp

34 itional cases, for a total of 7,006 incident breast cancer cases (1976-2002).

35 trate these methods using a series of 25,962 breast cancer cases (1988-2004) from the West Midlands,

36 years of additional follow-up, 104 incident breast cancer cases, 20 of which appeared in women with

37 a nested case-control study of 302 women (69 breast cancer cases, 233 controls) who had been initiall

38 population-based case-control studies (3,468 breast cancer cases; 3,578 controls age 30-69 years) and

39 based study in North Carolina comprising 791 breast cancer cases (302 in African-American women and 4

40 Of 510 male breast cancer cases (456 white, 34 black), 94% underwent

41 e population was estimated to capture 37% of breast cancer cases, 46% of prostate cancer cases, 34% o

42 son-years of follow-up, we documented 10,602 breast cancer cases (6689 NHS, 3913 NHSII).

43 2002) of postmenopausal Caucasian women (522 breast cancer cases, 708 controls).

44 n 4.3 million fewer cHT users, 126,000 fewer breast cancer cases, 76,000 fewer cardiovascular disease

45 at P </= 1 x 10(-5) in an additional 11 209 breast cancer cases (946 with ER-negative disease) and 1

46 d 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 de

47 tions on informal caregiving; 1,700 incident breast cancer cases accrued over follow-up to 2000.

48 ed, North Carolina case-control study of 862 breast cancer cases aged 20-74 years diagnosed during 19

49 exican women during 1992-1994 using incident breast cancer cases aged 35-74 years and frequency-match

50 Breast cancer cases aged 50-79 years (n = 5,559) and end

51 In a Swedish family with five breast cancer cases, all analyzed tumors showed distinct

52 Invasive breast cancer cases among women from 1997 to 2011 were a

53 umor tissues showed no mutation in the index breast cancer case and revealed the presence of at least

54 yped rs2735383 in 1,170 familial non-BRCA1/2 breast cancer cases and 1,077 controls using PCR-based r

55 cted 24 SNPs for further genotyping in 1,516 breast cancer cases and 1,189 noncancer controls.

56 A total of 1,434 breast cancer cases and 1,440 controls provided adequate

57 MR was undertaken in 122,977 breast cancer cases and 105,974 controls, including 69,5

58 ome-wide association study including 133,384 breast cancer cases and 113,789 controls, plus 18,908 BR

59 e-wide association studies, including 10,052 breast cancer cases and 12,575 controls of European ance

60 tion studies among 10,146 non-Hispanic white breast cancer cases and 12,760 controls within the Natio

61 A case-control study was conducted among 120 breast cancer cases and 120 controls.

62 ene in breast cancer risk in a study of 1193 breast cancer cases and 1310 matched controls from the S

63 00 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.

64 ropean-ancestry women using data from 17,262 breast cancer cases and 17,695 controls of Asian ancestr

65 meta-analysis of 11 GWAS, comprising 15,748 breast cancer cases and 18,084 controls together with 46

66 A total of 304 breast cancer cases and 186 controls aged 40-79 years we

67 udy consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherla

68 A total of 293 breast cancer cases and 240 controls with at least one o

69 e association study data from 172,737 female breast cancer cases and 242,009 controls of African, Asi

70 ted with breast cancer among 2,604 Caucasian breast cancer cases and 3,118 matched controls.

71 g data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 302,116 controls from three stud

72 ide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of

73 reast cancer risk among 268 family sets (287 breast cancer cases and 350 sister controls).

74 re estimated by using data on 3,499 invasive breast cancer cases and 4,213 controls from a population

75 stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a th

76 The authors compared 5,358 newly diagnosed breast cancer cases and 4,555 controls interviewed from

77 region around CASP8 were genotyped in 46 450 breast cancer cases and 42 600 controls of European orig

78 14q24.1 (RAD51L1), for up to 46 036 invasive breast cancer cases and 46 930 controls from 39 studies.

79 rs2735383 genotypes (r(2) > 0.999) of 47,640 breast cancer cases and 46,656 controls from the Breast

80 CYP1A1 by PCR-RFLP assays among 466 incident breast cancer cases and 466 matched controls.

81 actor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast

82 NCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European desc

83 sed these to construct risk scores for 3,628 breast cancer cases and 5,190 controls from the UK2 GWAS

84 unohistochemistry, we evaluated 306 invasive breast cancer cases and 52 normal tissue samples.

85 otyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a simi

86 Among a subgroup of 362 breast cancer cases and 611 matched controls with plasma

87 control study in 621 postmenopausal invasive breast cancer cases and 621 matched controls in the mult

88 nested case-control study consisting of 604 breast cancer cases and 626 controls with prospectively

89 alysis of genotyping data from 8635 familial breast cancer cases and 6625 controls from different cou

90 his study was conducted among 5,356 invasive breast cancer cases and 7,129 controls comprised primari

91 This study includes 5,370 breast cancer cases and 7,480 matched controls from five

92 gnostic first-morning urine samples from 251 breast cancer cases and 727 matched controls.

93 hed case-control study identified 735 female breast cancer cases and 735 female controls without brea

94 es collected between 1996 and 1999 among 600 breast cancer cases and 786 matched controls.

95 We genotyped 733 hospital-based breast cancer cases and 839 controls for 10 haplotype-ta

96 gas chromatography mass spectrometry for 436 breast cancer cases and 852 individually matched control

97 DNA (saliva) was available for 920 breast cancer cases and 960 controls.

98 from the FGFR2 region, in 950 consecutive AJ breast cancer cases and 979 age-matched AJ controls.

99 ream of the transcription start site) in 947 breast cancer cases and 993 age frequency-matched commun

100 principal components factor analysis in 1097 breast cancer cases and an age-stratified subcohort of 3

101 Here, in a larger sample of breast cancer cases and controls (n = 1,322/n = 1,953) n

102 c markers to estimate the ancestry of Latina breast cancer cases and controls and assessed the associ

103 content of adipose tissue in postmenopausal breast cancer cases and controls from five European coun

104 SR1 gene variants (SNPs) in more than 55,000 breast cancer cases and controls from studies within the

105 as validated, compared with self-report, for breast cancer cases and controls in Utah and New Mexico.

106 Breast cancer cases and controls were identified through

107 ography; and the number of radiation-induced breast cancer cases and deaths associated with different

108 Breast cancer cases and estrogen receptor and progestero

109 trieved several prediagnostic mammograms for breast cancer cases and for controls frequency-matched t

110 Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours.

111 iants (PVs) in unselected, 'population-type' breast cancer cases and their association with breast ca

112 Bilateral breast cancer cases and their families are likely to pro

113 ologic information databases that identified breast cancer cases and tumor characteristics.

114 nt fraction (~20-25%) of all newly diagnosed breast cancer cases and, if left untreated, a significan

115 Us) and malignant epithelial samples from 18 breast cancer cases, and examined their DNA for LOH at 2

116 D-BP gene is amplified in one-third of human breast cancer cases, and the CRD-BP appears to be an onc

117 Between 5% and 10% of breast cancer cases are associated with an inherited ger

118 Families with three or more breast cancer cases are being used in traditional linkag

119 70% of all breast cancer cases are estrogen receptor (ER)-positive

120 Approximately two thirds of all breast cancer cases are estrogen receptor (ER)-positive.

121 A population-based series of 469 bilateral breast cancer cases ascertained through English cancer r

122 This study analyzed breast cancer cases at King Fahad Specialist Hospital-Da

123 , 3.61; 95% CI, 1.11-11.7; percentage of all breast cancer cases attributable to this risk factor, 2.

124 , 5.65; 95% CI, 1.50-21.3; percentage of all breast cancer cases attributable to this risk factor, 2.

125 e, but not GrimAge), and when stratifying by breast cancer case (beta(WTC Exposed vs. Unexposed): 3.4

126 that overexpression of FOXN3 gene in Indian breast cancer cases can have a potential role in breast

127 tion of one intragenic repetitive element in breast cancer cases compared with controls (P = 0.0017),

128 was significantly higher in triple-negative breast cancer cases compared with normal mammary tissues

129 yped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study.

130 el and then evaluate their human homologs in breast cancer case-control association studies.

131 When it was applied to a sporadic breast cancer case-control data set, in the absence of a

132 variable in a logistic regression model with breast cancer case-control status as the outcome.

133 th use of multivariable logistic regression, breast cancer case-control status was regressed on terti

134 st cancer was tested in two population-based breast cancer case-control studies (approximately 12,000

135 Breast cancer case-control studies are being used to loo

136 as controls in one of two population-based, breast cancer case-control studies conducted in Los Ange

137 By evaluation of these SNPs in five breast cancer case-control studies involving more than 2

138 We analyzed data from a breast cancer case-control study (105 patients, 266 cont

139 ic association studies in a population-based breast cancer case-control study analysing polymorphisms

140 We applied the new assay to a breast cancer case-control study and identified the +/+

141 However, an Australian breast cancer case-control study found no association wi

142 bility (average Rh2=0.92) and genotyped in a breast cancer case-control study in the MEC (cases, n=13

143 erage R(h)(2) = 0.94) and were examined in a breast cancer case-control study in the Multiethnic Coho

144 mon BRCA2 haplotypes and were genotyped in a breast cancer case-control study nested in the MEC (case

145 ed for African Americans) and genotyped in a breast cancer case-control study nested in the Multiethn

146 associated with TNBC in a prospective nested breast cancer case-control study within the Generations

147 y of 600 middle-aged men and women, and in a breast cancer case-control study, comprised 4647 cases a

148 ion with breast cancer risk in a Mayo Clinic breast cancer case-control study.

149 he Nurses' Health Study, with 1,506 invasive breast cancer cases diagnosed after blood donation in 19

150 primary, histologically confirmed, invasive breast cancer cases diagnosed among women aged at least

151 emale Swedish hemangioma patients with 1,079 breast cancer cases diagnosed between 1958 and 2013, exp

152 trol study in the Nurses' Heath Study of 726 breast cancer cases diagnosed between June 1, 1992, and

153 The study included 1,687 incident breast cancer cases diagnosed from 1989 to 2000 and 4,70

154 a retrospective case-only study of 8860 AYA breast cancer cases diagnosed from 1997 to 2006 using th

155 Breast cancer cases diagnosed in 1999-2004 were identifi

156 Breast cancer cases during a mean (SD) follow-up of 9.3

157 identifying inherited pathogenic variants in breast cancer cases from Puerto Rico that were not linke

158 A population-based series of 54 male breast cancer cases from Southern California were analyz

159 geons with higher volumes and percentages of breast cancer cases had a higher likelihood of undergoin

160 an average of 7.6 y, 2879 incident invasive breast cancer cases had been ascertained, of whom 2509 h

161 As of 31 December 2005, 629 incident breast cancer cases had been diagnosed among the 34,028

162 Only 3 of the breast cancer cases had no immunohistochemical evidence

163 Breast cancer cases had significantly lower (mean +/- SD

164 No incidence of breast cancer cases has ever been reported in the popula

165 Analyses included 1,343 incident breast cancer cases identified during follow-up from 199

166 The analyses were limited to breast cancer cases identified during the period 1985-19

167 valence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and

168 nits are frequently overexpressed in primary breast cancer cases in a correlative manner.

169 ive life, the authors evaluated 906 incident breast cancer cases in a nationwide cohort of 56,042 fem

170 rsus placebo (calculated as 1 - the ratio of breast cancer cases in the anastrozole group to cases in

171 reast cancer cases to the observed number of breast cancer cases in the cohort, and on the basis of t

172 proximately one-third of all newly diagnosed breast cancer cases in the United States and constitutes

173 carcinoma in situ (DCIS) accounts for 20% of breast cancer cases in the United States and is potentia

174 breast cancer (TNBC) accounts for 15-20% of breast cancer cases in the United States, lacks targeted

175 BRCA2 mutations, accounts for 5%-10% of all breast cancer cases in the United States.

176 g adults [AYAs]) constitutes 5% to 6% of all breast cancer cases in the United States.

177 Overall, 15.0% (95% CI, 12.8%-17.4%) of breast cancer cases in this population may be attributab

178 spective analysis among 188,860 women (7,582 breast cancer cases) in the Nurses' Health Study (1988-2

179 We compared 168 breast-cancer cases incident by 2000 with four matched c

180 od 15 June 1990-15 June 2008, 5,956 incident breast cancer cases (including 5,245 invasive tumors) we

181 A total of 304 incident breast cancer cases (including 62 in situ carcinomas) an

182 Up to 30% of all breast cancer cases may be inherited and up to 85% of th

183 We postulated that breast cancer cases might have a higher prevalence of lo

184 Breast cancer cases (n = 1,199) were identified through

185 alidated in an additional independent set of breast cancer cases (n = 10).

186 Incident breast cancer cases (n = 11,943) were confirmed with med

187 A small number of breast cancer cases (n = 2) limited the statistical powe

188 Primary breast cancer cases (n = 2,325) in the 4-Corners region

189 Breast cancer cases (N = 247) diagnosed between collecti

190 Breast cancer cases (N = 4,935) aged 50-79 years were id

191 Population-based Hispanic breast cancer cases (n = 492) enrolled in the Northern C

192 Subjects were incident breast cancer cases (N = 497) and a subcohort (N = 2,830

193 screening was performed for Northern Finnish breast cancer cases (n = 578-1565) and controls (n = 337

194 Breast cancer cases (n = 7,591) were matched 1:4 to cont

195 A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37

196 Through December 31, 1992, 879 incident breast cancer cases occurred in this cohort.

197 ohort from 1971 to 1993, 221 and 66 incident breast cancer cases occurred, respectively.

198 The studies included 7377 incident invasive breast cancer cases occurring among 351 825 women whose

199 epresents 15-20% of the over one million new breast cancer cases occurring each year.

200 randomly selected controls and 850 incident breast cancer cases of the first four ethnic groups who

201 s at breast MR imaging--were matched to each breast cancer case on the basis of age and date of MR im

202 us was defined using age as a proxy, whereby breast cancer cases or deaths at age 50 years or older w

203 dential histories of 1,508 participants with breast cancer (case participants) and 1,556 particpants

204 predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected wome

205 s considered rare, constituting only 2-4% of breast cancer cases, poor prognosis means that patients

206 We identified T1a,bN0M0 breast cancer cases registered in the SEER Program from

207 We reviewed T1a,bN0M0 breast cancer cases registered in the Surveillance, Epid

208 Between 5% and 10% of breast cancer cases result from an inherited predisposit

209 encing in a multiethnic panel of 95 advanced breast cancer cases revealed no common missense variant

210 The examples are in the form of breast cancer case studies, and the data sets were procu

211 In triple-negative breast cancer case studies, G2D-Diff generated plausible

212 s of test area under ROC Curve (AUC), on all breast cancer case studies.

213 d and evaluated the proposed methods on five breast cancer case studies.

214 For the breast cancer case study using the full training set, th

215 Using the reduced training set in the breast cancer case study, the cumulative precision of ou

216 arger effect sizes in this study of familial breast cancer cases than in previous population-based st

217 alth Study (1997-2008) including 718 Chinese breast cancer cases, the authors evaluated baseline diet

218 cs is believed to account for only 10-15% of breast cancer cases, the environment, including nutritio

219 122,978 women in the FinnGen study with 8401 breast cancer cases, the PRS modifies the breast cancer

220 lse-positive controls were compared with the breast cancer cases: The ORs for moderate or marked BPE

221 In human breast cancer cases, there was a strong inverse correlat

222 We documented 1,700 invasive breast cancer cases through 2015 (mean follow-up, 7.6 y)

223 available microarray datasets comprising 674 breast cancer cases to systematically investigate how ex

224 based on the ratio of the expected number of breast cancer cases to the observed number of breast can

225 erformed a retrospective cohort study of all breast cancer cases treated from January 1, 2000, to May

226 nd 2 play a role only in a small fraction of breast cancer cases, understanding the genetic risk of t

227 and BRCA2 in the lymphocytes of non-familial breast cancer cases versus controls (BRCA1: 0.353, P = 0

228 1.5-57.0); the median surgeon percentage of breast cancer cases was 4.5% (range, 0.4%-100.0%).

229 The median annual surgeon Medicare volume of breast cancer cases was 6.0 (range, 1.5-57.0); the media

230 erience after first relapse in 1,696 primary breast cancer cases was analyzed using Cox proportional

231 When the age at diagnosis of the breast cancer cases was examined by OCCR, cases associat

232 The PV frequency in 'population-type' breast cancer cases was very low for 'syndromic' BCSGs T

233 llow-up period of 7.1 years (1987-1995), 187 breast cancer cases were ascertained.

234 Incident invasive breast cancer cases were confirmed by medical record rev

235 During follow-up, 1016 first incident breast cancer cases were diagnosed (431 premenopausal, 5

236 e first blood collection and June 2010, 2188 breast cancer cases were diagnosed (579 cases were diagn

237 Between 1995 and 2008, 2482 invasive breast cancer cases were diagnosed among 57,403 postmeno

238 A total of 2,416 breast cancer cases were diagnosed during follow-up (mea

239 premenopausal and 1.4 million postmenopausal breast cancer cases were diagnosed worldwide in 2018, wi

240 ow-up (513,015 person-years), 1,459 invasive breast cancer cases were diagnosed.

241 During follow-up, a total of 5,483 invasive breast cancer cases were diagnosed.

242 low-up through June 30, 2007, 4,084 invasive breast cancer cases were diagnosed.

243 average of 7.35 y of follow-up, 616 incident breast cancer cases were documented.

244 and frequencies of PVs in 'population-type' breast cancer cases were generated for BRCA1 (OR 8.73, 9

245 omen followed for a median of 8.5 years, 109 breast cancer cases were identified and frequency-matche

246 Incident breast cancer cases were identified through linkage with

247 Incident breast cancer cases were identified through the New Jers

248 Through 2000, 309 incident breast cancer cases were identified via population-based

249 Breast cancer cases were identified via the Finnish Canc

250 During an average of 7 y of follow-up, 5461 breast cancer cases were identified, of which 3341 cases

251 ng an average of 7 years of follow-up, 5,461 breast cancer cases were identified.

252 hrough June 1, 1994, 1,761 incident invasive breast cancer cases were identified.

253 ollow-up (2004 to 2011), 2,407 first primary breast cancer cases were identified.

254 r and Nutrition cohort, 1502 female incident breast cancer cases were included, with an oversampling

255 Patients with breast cancer (cases) were diagnosed following a mammogr

256 Retrospective analysis of 372 breast cancer cases with assessable immunohistochemical

257 women between 1993-1996 and 2004/2005, 2,543 breast cancer cases with data on ER/PR status were ident

258 pes in 164 Caucasian and 59 African-American breast cancer cases with those in age-, race-, and frequ

259 R337H variant may contribute to 2.36% of the breast cancer cases without family cancer history in Par